logo
logo

Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million

Sep 16, 2020•almost 5 years ago

Round Type

series a

Basel

Description

Polyneuron Pharmaceuticals AG, a clinical stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, today announced a CHF 14 million extension of the Series A, bringing the total to CHF 36.5 million. HBM Healthcare Investments has joined the consortium of investors in the Series A, led by Sofinnova Partners, and which included New Enterprise Associates (NEA) and other private investors.

Company Information

Company

Polyneuron

Location

Basel, Basel-City, Switzerland

About

Polyneuron Pharmaceuticals is pioneering a novel therapeutic approach for the effective and safe treatment of antibody-mediated immune diseases. The company’s Antibody-Catch™ technology platform enables the chemical design of injectable polymers that are able to selectively eliminate pathological antibodies in an antigen-specific manner, while leaving the rest of the immune system intact. Polyneuron was founded as a University of Basel, Department of Pharmaceutical Sciences, spin-off in 2014 by Dr. Ruben Herrendorff (CEO), Dr. Pascal Hänggi (CSO), Prof. Beat Ernst and Prof. Dr. med. Andreas J. Steck. The company is headquartered at the Stücki Park in Basel, Switzerland. More information can be found at http://www.polyneuron.com/.

FundzWatch™ Score

81
Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood

Related People